• Home
  • Search Results
  • Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.

Clinical and experimental immunology (1997-11-21)
J D Isaacs, N Burrows, M Wing, M T Keogan, P R Rebello, R A Watts, R J Pye, P Norris, B L Hazelman, G Hale, H Waldmann

We have investigated the biological and therapeutic properties of a humanized anti-CD4 MoAb, hIgG1-CD4, in patients with refractory psoriasis and rheumatoid arthritis (RA). hIgG1-CD4 is a modulating, non-depleting MoAb, which induced a first-dose reaction in most patients treated. It provided brief symptomatic relief in both conditions, and psoriasis appeared easier to control with conventional agents after MoAb therapy. At the doses used, hIgG1-CD4 did not synergize therapeutically with the panlymphocyte MoAb CAMPATH-1H (C1H) in patients with RA treated sequentially with both agents. There were no serious adverse effects definitely attributable to therapy. Our results are compared with those of other CD4 MoAb studies, and factors influencing the outcome of therapy are discussed.

Product Number
Product Description

Monoclonal Anti-Human IgG1−FITC antibody produced in mouse, clone 8c/6-39, purified immunoglobulin, buffered aqueous solution

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.